![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ARHGAP35 |
Gene summary for ARHGAP35 |
![]() |
Gene information | Species | Human | Gene symbol | ARHGAP35 | Gene ID | 2909 |
Gene name | Rho GTPase activating protein 35 | |
Gene Alias | GRF-1 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9NRY4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2909 | ARHGAP35 | CA_HPV_2 | Human | Cervix | CC | 6.92e-03 | 2.37e-01 | 0.0391 |
2909 | ARHGAP35 | CCI_2 | Human | Cervix | CC | 1.53e-03 | 5.15e-01 | 0.5249 |
2909 | ARHGAP35 | CCI_3 | Human | Cervix | CC | 2.99e-09 | 7.42e-01 | 0.516 |
2909 | ARHGAP35 | LZE2T | Human | Esophagus | ESCC | 7.30e-03 | 5.68e-01 | 0.082 |
2909 | ARHGAP35 | LZE4T | Human | Esophagus | ESCC | 1.68e-04 | 2.24e-01 | 0.0811 |
2909 | ARHGAP35 | LZE7T | Human | Esophagus | ESCC | 9.73e-04 | 2.16e-01 | 0.0667 |
2909 | ARHGAP35 | LZE20T | Human | Esophagus | ESCC | 3.89e-04 | 1.02e-01 | 0.0662 |
2909 | ARHGAP35 | LZE24T | Human | Esophagus | ESCC | 1.37e-12 | 2.26e-01 | 0.0596 |
2909 | ARHGAP35 | LZE21T | Human | Esophagus | ESCC | 3.21e-03 | 2.81e-01 | 0.0655 |
2909 | ARHGAP35 | P1T-E | Human | Esophagus | ESCC | 7.87e-06 | 3.14e-01 | 0.0875 |
2909 | ARHGAP35 | P2T-E | Human | Esophagus | ESCC | 1.33e-08 | 1.17e-01 | 0.1177 |
2909 | ARHGAP35 | P4T-E | Human | Esophagus | ESCC | 7.36e-09 | 1.63e-01 | 0.1323 |
2909 | ARHGAP35 | P5T-E | Human | Esophagus | ESCC | 3.95e-02 | -1.07e-03 | 0.1327 |
2909 | ARHGAP35 | P8T-E | Human | Esophagus | ESCC | 1.22e-25 | 6.39e-01 | 0.0889 |
2909 | ARHGAP35 | P9T-E | Human | Esophagus | ESCC | 3.34e-11 | 1.43e-01 | 0.1131 |
2909 | ARHGAP35 | P10T-E | Human | Esophagus | ESCC | 2.20e-24 | 4.35e-01 | 0.116 |
2909 | ARHGAP35 | P12T-E | Human | Esophagus | ESCC | 8.36e-17 | 2.68e-01 | 0.1122 |
2909 | ARHGAP35 | P15T-E | Human | Esophagus | ESCC | 5.88e-25 | 5.03e-01 | 0.1149 |
2909 | ARHGAP35 | P16T-E | Human | Esophagus | ESCC | 9.98e-04 | 6.79e-02 | 0.1153 |
2909 | ARHGAP35 | P17T-E | Human | Esophagus | ESCC | 5.48e-03 | 1.54e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:00071639 | Cervix | CC | establishment or maintenance of cell polarity | 63/2311 | 218/18723 | 4.25e-11 | 8.76e-09 | 63 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
GO:00443193 | Cervix | CC | wound healing, spreading of cells | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
GO:00905053 | Cervix | CC | epiboly involved in wound healing | 17/2311 | 34/18723 | 9.86e-08 | 5.25e-06 | 17 |
GO:00905043 | Cervix | CC | epiboly | 17/2311 | 35/18723 | 1.70e-07 | 7.93e-06 | 17 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:00020111 | Cervix | CC | morphogenesis of an epithelial sheet | 21/2311 | 57/18723 | 1.91e-06 | 5.97e-05 | 21 |
GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00313467 | Cervix | CC | positive regulation of cell projection organization | 72/2311 | 353/18723 | 1.04e-05 | 2.32e-04 | 72 |
GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa0451014 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa04670110 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0461113 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa04510111 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0467014 | Liver | NAFLD | Leukocyte transendothelial migration | 25/1043 | 114/8465 | 2.65e-03 | 2.71e-02 | 2.19e-02 | 25 |
hsa045106 | Liver | NAFLD | Focal adhesion | 38/1043 | 203/8465 | 5.13e-03 | 4.43e-02 | 3.57e-02 | 38 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0467015 | Liver | NAFLD | Leukocyte transendothelial migration | 25/1043 | 114/8465 | 2.65e-03 | 2.71e-02 | 2.19e-02 | 25 |
hsa0451011 | Liver | NAFLD | Focal adhesion | 38/1043 | 203/8465 | 5.13e-03 | 4.43e-02 | 3.57e-02 | 38 |
hsa0451021 | Liver | Cirrhotic | Focal adhesion | 93/2530 | 203/8465 | 9.27e-07 | 1.10e-05 | 6.80e-06 | 93 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ARHGAP35 | insertion | Frame_Shift_Ins | novel | c.1445dupA | p.Gln483AlafsTer5 | p.Q483Afs*5 | Q9NRY4 | protein_coding | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | ||
ARHGAP35 | SNV | Missense_Mutation | c.2906N>T | p.Asn969Ile | p.N969I | Q9NRY4 | protein_coding | tolerated(0.14) | benign(0.137) | TCGA-CC-A7II-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
ARHGAP35 | SNV | Missense_Mutation | novel | c.1378N>G | p.Met460Val | p.M460V | Q9NRY4 | protein_coding | deleterious(0.02) | benign(0.198) | TCGA-DD-AADO-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ARHGAP35 | SNV | Missense_Mutation | novel | c.3080N>A | p.Ser1027Asn | p.S1027N | Q9NRY4 | protein_coding | tolerated(0.52) | benign(0.006) | TCGA-DD-AAE6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ARHGAP35 | SNV | Missense_Mutation | rs779738931 | c.848G>A | p.Arg283His | p.R283H | Q9NRY4 | protein_coding | tolerated(0.35) | benign(0.007) | TCGA-FV-A23B-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARHGAP35 | SNV | Missense_Mutation | c.3587N>T | p.Gln1196Leu | p.Q1196L | Q9NRY4 | protein_coding | tolerated(0.25) | benign(0) | TCGA-MI-A75E-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ARHGAP35 | SNV | Missense_Mutation | novel | c.523G>T | p.Asp175Tyr | p.D175Y | Q9NRY4 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-44-2659-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | alimta | PD |
ARHGAP35 | SNV | Missense_Mutation | novel | c.3827N>T | p.Gly1276Val | p.G1276V | Q9NRY4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ARHGAP35 | SNV | Missense_Mutation | novel | c.1860N>G | p.Cys620Trp | p.C620W | Q9NRY4 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-49-4488-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ARHGAP35 | SNV | Missense_Mutation | c.565G>A | p.Ala189Thr | p.A189T | Q9NRY4 | protein_coding | tolerated(0.33) | benign(0.003) | TCGA-49-4507-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |